GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present groundbreaking data on its COVID-19 vaccine candidates at the prestigious Keystone Symposia on Vaccinology. The presentations will focus on the cross-reactivity and broad-spectrum immunity of GEO-CM04S1 and GeoVax's multi-antigen vaccine technology, offering hope for more effective protection against SARS-CoV-2 and its variants.
The first presentation, led by GeoVax Scientist Pratima Kumari, PhD, will detail how MVA-vectored multi-antigen COVID-19 vaccines induce protective immunity against SARS-CoV-2 variants from Alpha to Omicron in preclinical models. The second, by Georgia State University Scientist Amany Elsharkawy, PhD, will explore the GEO-CM04S1 vaccine candidate's cross-reactivity against the original SARS-CoV-2 B.1 and Omicron subvariant XBB.1.5.
Mark Newman, PhD, GeoVax's Chief Scientific Officer, emphasized the importance of these findings for populations where current vaccines have fallen short, particularly immunocompromised patients. The data underscores the potential of GeoVax's technology to address the challenges posed by rapidly evolving viruses, marking a significant step forward in the global fight against COVID-19.
This development is crucial as it highlights the ongoing need for innovative vaccine technologies that can adapt to new variants, ensuring broader and more durable protection. The presentations at the Keystone Symposia not only showcase GeoVax's leadership in vaccine development but also contribute to the collective knowledge and tools needed to combat future pandemics.
